Oncology Institute (TOI) Liabilities and Shareholders Equity (2019 - 2026)

Oncology Institute has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $168.2 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 2.58% year-over-year to $168.2 million; the trailing twelve-month figure through Mar 2026 stood at $656.3 million (down 5.64% YoY), and the FY2025 full-year result was $164.7 million, down 4.67% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $168.2 million, up from $164.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $283.8 million in Q3 2022, with the low at $159.8 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $199.4 million across 5 years, with a median of $189.7 million in 2022.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity advanced 28.62% — and 2023, when it slipped 23.06%.
• Oncology Institute's Liabilities and Shareholders Equity stood at $261.7 million in 2022, then declined by 20.04% to $209.2 million in 2023, then slipped by 17.46% to $172.7 million in 2024, then retreated by 4.67% to $164.7 million in 2025, then increased by 2.17% to $168.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $168.2 million (Q1 2026), $164.7 million (Q4 2025), and $163.6 million (Q3 2025), per Business Quant data.